Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.
Contact
Daeryung Technotown 17
Suite 1401
Gasan Digital 1-ro 25
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
125
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,966.70 | 3.20 | 0.04% |
CAC 40 | 7,854.13 | 53.25 | 0.68% |
DAX 40 | 24,204.99 | 234.63 | 0.98% |
Dow JONES (US) | 44,701.36 | 136.20 | -0.30% |
FTSE 100 | 9,141.12 | 59.68 | 0.66% |
HKSE | 25,524.45 | 37.68 | -0.15% |
NASDAQ | 21,156.95 | 21.63 | -0.10% |
Nikkei 225 | 40,674.55 | 323.72 | -0.79% |
NZX 50 Index | 12,936.41 | 25.67 | 0.20% |
S&P 500 | 6,383.96 | 5.81 | -0.09% |
S&P/ASX 200 | 8,704.60 | 6.90 | 0.08% |
SSE Composite Index | 3,609.71 | 11.77 | 0.33% |